Sandip I. Patel
Known title: CFO & General CounselCIK: 0001843601
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Transaction History
| ATCH | ▲ Buy | Grant | 50,000 | $10K | 9/25/2026 | View on chart |
| ATCH | ▲ Buy | Grant | 50,000 | $11K | 9/24/2026 | View on chart |
| AKTX | ▲ Buy | Grant | 44,642 | $50K | 3/6/2025 | View on chart |
| ATCH | ▼ Sell | Other | 201,860 | — | 2/9/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AtlasClear (ATCH) reports Q4 2026 results and insider share purchases
AtlasClear disclosed that five members of its executive leadership and board bought a total of 815,000 shares of common stock. The company also released its fiscal year 2026 results and held a Q4 earnings call, providing the latest financial performance. Insider buying and the earnings release together give investors additional information about management confidence and the company’s recent results.
AtlasClear (ATCH) reports Q4 2026 results and insider share purchases. AtlasClear disclosed that five members of its executive leadership and board bought a total of 815,000 shares of common stock. The company also released its fiscal year 2026 results and held a Q4 earnings call, providing the latest financial performance. Insider buying and the earnings release together give investors additional information about management confidence and the company’s recent results.